STOCK TITAN

Surrozen Announces Pricing of $60 Million Underwritten Offering of Common Stock

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Surrozen (Nasdaq: SRZN) priced an underwritten common stock offering expected to raise $60 million in gross proceeds for the company.

The offering comprises 1,894,540 shares at $31.67 per share, all sold by Surrozen. Gross proceeds exclude underwriting discounts, commissions and offering expenses. The company expects closing on or about November 16, 2026, subject to customary closing conditions. Participants include Access Biotechnology, Boxer Capital Management, Perceptive Advisors, RTW Investments and Venrock Healthcare Capital Partners.

Loading...
Loading translation...
1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Underwritten offering is expected to raise $60 million in gross proceeds for Surrozen. 11% of market cap

Negative

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Issuance of 1,894,540 common shares at $31.67 per share dilutes existing holders.

News Explained

At the third-quarter 2026 operating-cash-use rate, the expected $60 million gross proceeds equal 1,143.3 days of use, before offering costs.

The offering is priced but not yet closed, with closing expected on or about November 16, 2026, subject to customary conditions; if completed, Surrozen will issue 1,894,540 shares, increasing the share count and reducing existing holders’ percentage ownership.

The effective S-3 shelf permits later registered sales without a new registration each time; it authorizes capacity but does not itself sell shares, while this offering is being made under it.

Sources and calculations
  • Offering gross against the last reported quarterly operating outflow, in days at that rate $60,000,000 / ($4,828,000 / 92) = 1143.3 days

Key Figures

Shares offered: 1,894,540 shares Offering price: $31.67 per share Expected gross proceeds: $60 million +1 more
Shares offered
1,894,540 shares
Common stock sold by Surrozen
Offering price
$31.67 per share
Underwritten offering
Expected gross proceeds
$60 million
Before underwriting discounts, commissions and offering expenses
Expected closing
On or about November 16, 2026
Subject to customary closing conditions

Key Terms

underwritten offering, shelf registration statement, form s-3, prospectus supplement
4 terms
underwritten offering financial
"pricing of an underwritten offering of 1,894,540 shares"
An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.
shelf registration statement regulatory
"made pursuant to a shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
form s-3 regulatory
"a shelf registration statement on Form S-3"
Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.
prospectus supplement regulatory
"by means of a prospectus supplement to be filed with the SEC"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the pricing of an underwritten offering of 1,894,540 shares of its common stock at an offering price of $31.67 per share. The gross proceeds to Surrozen from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Surrozen, are expected to be $60 million. All the shares in the offering are being sold by Surrozen. The offering is expected to close on or about November 16, 2026, subject to the satisfaction of customary closing conditions.

The offering includes participation from Access Biotechnology, Boxer Capital Management, Perceptive Advisors, RTW Investments, Venrock Healthcare Capital Partners, and other new and existing life sciences focused investors.

Morgan Stanley, Guggenheim Securities and Cantor are acting as joint book-running managers for the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-294542) that was previously filed with the U.S. Securities and Exchange Commission (“SEC”) on March 23, 2026 and was declared effective by the SEC on March 30, 2026. This offering is being made only by means of a prospectus supplement to be filed with the SEC and an accompanying prospectus that form a part of the effective registration statement. When available, copies of the prospectus supplement and the accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: (212) 518-9544, email: GSEquityProspectusDelivery@guggenheimsecurities.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022; email: prospectus@cantor.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Surrozen
Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to harness the power of Wnt signaling to treat sight-threatening ophthalmic conditions. Built on deep scientific expertise and a proprietary antibody-engineering platform, Surrozen develops multifunctional biologics that selectively activate Wnt signaling in combination with other key disease pathways. Our approach aims to deliver best-in-class, durable therapies that have the potential to transform patient outcomes in some of the most pressing unmet medical needs in ocular diseases.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the completion of the offering. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the uncertainties related to the satisfaction of customary closing conditions for the offering, and all other factors discussed in the prospectus supplement and accompanying prospectus, Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 23, 2026 and Surrozen’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 9, 2026, under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law.

Investor and Media Contact:
Investorinfo@surrozen.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much will Surrozen's offering raise, and what is the share price?

Surrozen expects $60 million in gross proceeds from an offering of 1,894,540 common shares at $31.67 per share. All shares are being sold by Surrozen; gross proceeds are before underwriting discounts, commissions and offering expenses.

When is Surrozen's common stock offering expected to close?

Surrozen expects the offering to close on or about November 16, 2026, subject to satisfaction of customary closing conditions.

Keep reading